Fig 1: Circulating ligands of CXCR3 and CXCR3 expressing T cells in inflamed regions were elevated. (A) FACS gating of the Cluster 22. (B) The frequencies of CyTOF events for Clusters 22 among non_irAE, all grades irAE, Grade 1–2 irAE, and Grade 3 groups. (C) The frequencies of CyTOF events for Clusters 22 between PR and SD/PD groups. (D) Levels of plasma CCL20 of patients from irAE and non_irAE groups. (E) Levels of plasma CXCL9 of patients from irAE and non_irAE groups. (F) Levels of plasma CXCL10 of patients from irAE and non_irAE groups. (G) Levels of plasma CXCL11 of patients from irAE and non_irAE groups. (H) Levels of plasma PF4V1 of patients from irAE and non_irAE groups. (I) Multiple immunochemistry staining of CD3 and CXCR3 in the lung biopsy sample from a Grade 2 immune‐related pneumonia (G2_ir_pneumonia) patient. (J) Multiple immunochemistry staining of CD3 and CXCR3 in the lung gross examination sample from a Grade 2 immune‐related rash (G2_ir_rash) patient. (K) Multiple immunochemistry staining of CD3 and CXCR3 in the colon biopsy sample from a Grade 2 immune‐related colitis (G2_ir_pneumonia) patient. (L) Multiple immunochemistry staining of CD3 and CXCR3 in the colon cancer specimen from a Grade 2 immune‐related rash (G2_ir_rash) patient. (M) CD39 expression levels in C20 among non_irAE, pneumonia, cutaneous irAE, other irAE, and non_cutaneous irAE groups. (N) CD45RA expression levels in C20 among non_irAE, pneumonia, cutaneous irAE, other irAE, and non_cutaneous irAE groups. (O) CD122 expression levels in C20 among non_irAE, pneumonia, cutaneous irAE, other irAE, and non_cutaneous irAE groups. (P) CXCR3 expression levels in C05 among non_irAE, pneumonia, cutaneous irAE, other irAE, and non_pneumonia groups. (Q) CXCR3 expression levels in C10 among non_irAE, pneumonia, cutaneous irAE, other irAE, and non_pneumonia groups.